{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T10:36:06Z","timestamp":1789641366118,"version":"4.0.0"},"reference-count":19,"publisher":"Informa UK Limited","issue":"12","license":[{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Viatris"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Delivery"],"published-print":{"date-parts":[[2025,12,2]]},"DOI":"10.1080\/17425247.2025.2561710","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T23:24:30Z","timestamp":1758065070000},"page":"1977-1984","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of the pharmacokinetics of MR-107A-02, a novel fast-absorbing formulation of meloxicam, versus standard meloxicam reference: a phase I study"],"prefix":"10.1080","volume":"22","author":[{"given":"Matthew A.","family":"Hummel","sequence":"first","affiliation":[{"name":"Viatris Inc","place":["Morgantown, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Shaw","sequence":"additional","affiliation":[{"name":"Viatris Inc","place":["Morgantown, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark Shiyao","family":"Liu","sequence":"additional","affiliation":[{"name":"Viatris Inc","place":["Morgantown, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amarnath","family":"Jaiswal","sequence":"additional","affiliation":[{"name":"Viatris Inc","place":["Hyderabad, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey P.","family":"Smith","sequence":"additional","affiliation":[{"name":"Viatris Inc","place":["Morgantown, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Bertoch","sequence":"additional","affiliation":[{"name":"CenExel JBR","place":["Salt Lake City, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,9,19]]},"reference":[{"key":"e_1_3_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcorm.2025.100490"},{"key":"e_1_3_9_4_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr7103a1"},{"key":"e_1_3_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2019.10.002"},{"key":"e_1_3_9_6_1","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200222120-00001"},{"key":"e_1_3_9_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.19.2947"},{"issue":"2","key":"e_1_3_9_8_1","first-page":"282","article-title":"Efficacy and safety of meloxicam in patients with rheumatoid arthritis","volume":"24","author":"Lemmel E","year":"1997","unstructured":"Lemmel E, Bolten W, Burgos-Vargas R, et al. Efficacy and safety of meloxicam in patients with rheumatoid arthritis. J Rheumatol. 1997;24(2):282\u2013290.","journal-title":"J Rheumatol"},{"issue":"3","key":"e_1_3_9_9_1","first-page":"253","article-title":"Clinical pharmacokinetics of meloxicam","volume":"47","author":"T\u00fcrck D","year":"1997","unstructured":"T\u00fcrck D, Busch U, Heinzel G, et al. Clinical pharmacokinetics of meloxicam. Arzneimittel-forschung. 1997;47(3):253\u2013258.","journal-title":"Arzneimittel-forschung"},{"issue":"3","key":"e_1_3_9_10_1","first-page":"436","article-title":"Dose response and safety study of meloxicam up to 22.5 mg daily in rheumatoid arthritis: a 12\u00a0week multicenter, double blind, dose response study versus placebo and diclofenac","volume":"29","author":"Furst DE","year":"2002","unstructured":"Furst DE, Kolba KS, Fleischmann R, et al. Dose response and safety study of meloxicam up to 22.5 mg daily in rheumatoid arthritis: a 12\u00a0week multicenter, double blind, dose response study versus placebo and diclofenac. J Rheumatol. 2002;29(3):436\u2013446.","journal-title":"J Rheumatol"},{"key":"e_1_3_9_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/35.suppl_1.39"},{"key":"e_1_3_9_12_1","doi-asserted-by":"publisher","DOI":"10.4103\/joacp.JOACP_133_18"},{"key":"e_1_3_9_13_1","doi-asserted-by":"publisher","DOI":"10.7324\/JAPS.2021.110218"},{"key":"e_1_3_9_14_1","doi-asserted-by":"publisher","DOI":"10.5530\/ijpi.2021.4.75"},{"key":"e_1_3_9_15_1","doi-asserted-by":"publisher","DOI":"10.22159\/ajpcr.2020.v13i2.34838"},{"issue":"1","key":"e_1_3_9_16_1","first-page":"26","article-title":"Solubility enhancement of poorly water soluble drugs by solid dispersion","volume":"3","author":"Chaturvedi A","year":"2012","unstructured":"Chaturvedi A, Verma A. Solubility enhancement of poorly water soluble drugs by solid dispersion. Int J Pharm Sci Res. 2012;3(1):26.","journal-title":"Int J Pharm Sci Res"},{"key":"e_1_3_9_17_1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.130749.1"},{"key":"e_1_3_9_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-015-3121-9"},{"key":"e_1_3_9_19_1","unstructured":"USFDA. Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products\u2014general considerations. 2003 [cited 2025 Jun 19]. Available from: https:\/\/www.fda.gov\/media\/88254\/download"},{"key":"e_1_3_9_20_1","doi-asserted-by":"publisher","DOI":"10.5414\/CPP47638"},{"key":"e_1_3_9_21_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S39024"}],"container-title":["Expert Opinion on Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17425247.2025.2561710","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T12:39:08Z","timestamp":1764592748000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17425247.2025.2561710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":19,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12,2]]}},"alternative-id":["10.1080\/17425247.2025.2561710"],"URL":"https:\/\/doi.org\/10.1080\/17425247.2025.2561710","relation":{},"ISSN":["1742-5247","1744-7593"],"issn-type":[{"value":"1742-5247","type":"print"},{"value":"1744-7593","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,19]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iedd20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iedd20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-08-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}